InnoCare Pharma Limited (HKG:9969)
12.05
-0.07 (-0.58%)
Nov 10, 2026, 4:08 PM HKT
InnoCare Pharma Employees
InnoCare Pharma had 1,388 employees as of June 30, 2026. The number of employees increased by 299 or 27.46% compared to the previous year. That makes InnoCare Pharma the 12,601st largest employer in the world and 899th in Hong Kong.
Employees
1,388
Change
299
Growth
27.46%
Revenue / Employee
2.83M HKD
Profits / Employee
1.15M HKD
Market Cap
25.62B
Employees Chart
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 1,388 | 299 | 27.46% |
| Dec 31, 2023 | 1,089 | 150 | 15.97% |
| Dec 31, 2022 | 939 | 218 | 30.24% |
| Dec 31, 2021 | 721 | 269 | 59.51% |
| Dec 31, 2020 | 452 | 238 | 111.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Shanghai Henlius Biotech | 4,082 |
| RemeGen | 3,145 |
| Shanghai Junshi Biosciences | 3,055 |
| Biocytogen Pharmaceuticals (Beijing) | 1,922 |
| Zai Lab | 1,784 |
| Keymed Biosciences | 1,768 |
InnoCare Pharma News
- 1 day ago - InnoCare Announces First Patient Dosed in Head-to-Head Registrational Phase III Trial of Mesutoclax with Azacitidine versus Venetoclax with Azacitidine in Treatment Naive AML in China - GlobeNewsWire
- 15 days ago - InnoCare Pharma Earnings release: Q3 2026 - Filings
- 15 days ago - InnoCare Pharma Slides: Q3 2026 - Filings
- 4 weeks ago - InnoCare Announces Approval of Registrational Phase III Trial of Mesutoclax in Combination with Orelabrutinib in Relapsed/ Refractory MZL in China - GlobeNewsWire
- 6 weeks ago - China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion - Reuters
- 2 months ago - InnoCare Pharma Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - InnoCare Pharma Earnings release: Q2 2026 - Filings
- 2 months ago - InnoCare Pharma Slides: Q2 2026 - Filings